Study: NRG-GY035: A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research
team will contact you within 5 to 7 business days.
Please understand that:
- The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does
not enroll you into the study, or guarantee that you qualify for the study.
- It is always your choice to participate.
Thanks again. Volunteers such as yourself are at the core of our work.